<DOC>
	<DOC>NCT02354846</DOC>
	<brief_summary>An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy with Tenofovir in HBsAg-positive Patients with Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED study)</brief_summary>
	<brief_title>An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<criteria>Males or females aged more than18 HBsAgpositive DLBCL patients (it is possible to enrol the patients with combined DLBCL and low grade lymphoma such as follicular lymphoma) Previously untreated DLBCL patients who are suitable for receiving RCHOP chemotherapy Serum ALT no more than 2 x ULN (including normal ALT) Life expectancy 6 months A negative serum or urine pregnancy test prior to treatment must be available both for pre menopausal women and for women who are no more than 1 years after the onset of menopause. Informed consent Other subtype of lymphoma except DLBCL DLBCL patients who are NOT suitable for receiving RCHOP chemotherapy OR plan to receive other chemotherapy patients had been treated with antiviral therapy known to have activity against HBV (e.g., alphainterferon, lamivudine, telbivudine, clevudine, adefovir, entecavir or tenofovir) within the previous 6 months. evidence of hepatocellular carcinoma. evidence of decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>